SEC Form 4 · accession 0001209191-18-006912
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Bodick
Officer — Chief Scientific Officer
Period of report
Feb 1, 2018
Accepted (ET)
Feb 2, 2018 · 4:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 1, 2018 | A | 10,000 | $0.00 | A | 74,605 | D | |
| Common Stock | holding | — | — | — | 1,000 | I | By Spouse | |
| Common StockF1 | holding | — | — | — | 388,683 | I | By Versant Development Fund III, LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $22.31 | Feb 1, 2018 | A | 40,000 | A | — | Jan 31, 2028 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1The shares are held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
- F2Twenty-five percent (25%) of the shares subject to the option shall vest one year after January 1, 2018; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of January 1, 2018, so that all of the shares subject to the option shall be vested four (4) years after January 1, 2018.